Literature DB >> 8825693

Side effects of ergotamine.

W J Meyler1.   

Abstract

Ergotamine has been used for many years in the treatment of migraine, although there is little formal clinical evidence that it is significantly more efficacious than placebo. A number of side effects associated with ergotamine have been reported in the literature, including myocardial infarction, ischaemia of limb extremities, and fibrotic changes. Long-term use has led to reported cases of ergotamine-induced headache, vascular reactivity, and subclinical ergotism. When the safety profile of this drug is considered, coupled with its debatable efficacy from a clinical review previously published, the resulting poor risk:benefit ratio brings into question the continued use of ergotamine as a migraine treatment and calls for better controlled trials of its efficacy, or lack of, in the acute treatment of migraine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825693     DOI: 10.1046/j.1468-2982.1996.1601005.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  13 in total

Review 1.  Serotonergic agents in the management of cluster headache.

Authors:  Giorgio Lambru; Manjit Matharu
Journal:  Curr Pain Headache Rep       Date:  2011-04

Review 2.  Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.

Authors:  S S Jhee; T Shiovitz; A W Crawford; N R Cutler
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis.

Authors:  Andrew J Dowson; David W Dodick; Volker Limmroth
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Almotriptan: a review of its use in migraine.

Authors:  Susan J Keam; Karen L Goa; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  An update on the blood vessel in migraine.

Authors:  K C Brennan; Andrew Charles
Journal:  Curr Opin Neurol       Date:  2010-06       Impact factor: 5.710

Review 6.  Zolmitriptan: a review of its use in migraine.

Authors:  C M Spencer; N S Gunasekara; C Hills
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 7.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

8.  Biochemistry. As good as chocolate.

Authors:  Krzysztof Palczewski; Philip D Kiser
Journal:  Science       Date:  2013-05-03       Impact factor: 47.728

9.  Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study.

Authors:  Maurits E L Arbouw; Kris L L Movig; Henk-Jan Guchelaar; Cees Neef; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2011-07-22       Impact factor: 2.953

Review 10.  Ergotamine and dihydroergotamine: a review.

Authors:  Marcelo E Bigal; Stewart J Tepper
Journal:  Curr Pain Headache Rep       Date:  2003-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.